Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies

[Guest guest]

BlankBiologic agent activity in chronic lymphocytic leukemia: a framework for

future therapies.

C Nabhan, N Dalal, J Mehta, and NE Kay

Leuk Lymphoma, March 1, 2011; 52(3): 374-86.

Oncology Specialists, S. C., Department of Medicine, Division of Hematology and

Oncology, Advocate Lutheran General Hospital, Park Ridge, IL, USA.

The previous decade has witnessed remarkable advances in our understanding and

treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided

patients with unprecedented remission rates and has improved survival compared

to chemotherapy alone. However, the availability of targeted therapies and

monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens

for this disease. In this article, we review available targeted and

non-chemotherapeutic agents for CLL, attempting to position these therapies in

the treatment paradigm of CLL in the era of risk stratification as we move

forward.

PMID: 21323519